With Russia and China having authorized COVID-19 vaccines, and the US Presidential elections in early November, the political pressure on pharma to come up with an approval in the USA is growing by the week.
But the industry issued a strong message that it will not be swayed by outside influence and will only seek approval once a candidate is supported by safety and efficacy data from a Phase III trial, during a meeting of pharma bosses hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Thursday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze